Enhanced Anticancer Activity of Nanoformulation of Dasatinib Against Triple-Negative Breast Cancer

Overview

Journal J Pers Med

Date 2021 Jul 2

PMID 34204015

Citations 13

Authors

Fatemah Bahman

Valeria Pittala

Mohamed Haider

Khaled Greish

Affiliations

Soon will be listed here.

Abstract

Triple negative breast cancer (TNBC) is the most aggressive breast cancer accounting for around 15% of identified breast cancer cases. TNBC lacks human epidermal growth factor receptor 2 (HER2) amplification, is hormone independent estrogen (ER) and progesterone receptors (PR) negative, and is not reactive to current targeted therapies. Existing treatment relies on chemotherapeutic treatment, but in spite of an initial response to chemotherapy, the inception of resistance and relapse is unfortunately common. Dasatinib is an approved second-generation inhibitor of multiple tyrosine kinases, and literature data strongly support its use in the management of TNBC. However, dasatinib binds to plasma proteins and undergoes extensive metabolism through oxidation and conjugation. To protect dasatinib from fast pharmacokinetic degradation and to prolong its activity, it was encapsulated on poly(styrene-co-maleic acid) (SMA) micelles. The obtained SMA-dasatinib nanoparticles (NPs) were evaluated for their physicochemical properties, in vitro antiproliferative activity in different TNBC cell lines, and in vivo anticancer activity in a syngeneic model of breast cancer. Obtained results showed that SMA-dasatinib is more potent against 4T1 TNBC tumor growth in vivo compared to free drug. This enhanced effect was ascribed to the encapsulation of the drug protecting it from a rapid metabolism. Our finding highlights the often-overlooked value of nanoformulations in protecting its cargo from degradation. Overall, results may provide an alternative therapeutic strategy for TNBC management.

Citing Articles

Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway.

Park J, Jung K, Jia D, Yang S, Attri K, Ahn S Cell Rep Med. 2025; 6(2):101941.

PMID: 39933530 PMC: 11866546. DOI: 10.1016/j.xcrm.2025.101941.

Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors.

Mukherjee S, Joshi V, Reddy K, Singh N, Das P, Datta P Asian J Pharm Sci. 2024; 19(6):100980.

PMID: 39640056 PMC: 11617995. DOI: 10.1016/j.ajps.2024.100980.

Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis.

Kaur J, Adhikari M, Sabol H, Anloague A, Khan S, Kurihara N Cancer Res. 2024; 84(23):3936-3952.

PMID: 39312185 PMC: 11611663. DOI: 10.1158/0008-5472.CAN-24-0857.

Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC).

Battogtokh G, Obidiro O, Akala E Cancers (Basel). 2024; 16(11).

PMID: 38893132 PMC: 11171312. DOI: 10.3390/cancers16112012.

Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis.

Adhikari M, Kaur J, Sabol H, Anloague A, Khan S, Kurihara N Res Sq. 2024; .

PMID: 38558984 PMC: 10980159. DOI: 10.21203/rs.3.rs-4047486/v1.

References

Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S . Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008; 14(2):352-9. DOI: 10.1158/1078-0432.CCR-07-4175. View

Thakur R, Trivedi R, Rastogi N, Singh M, Mishra D . Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep. 2015; 5:10194. PMC: 4431480. DOI: 10.1038/srep10194. View

Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

Yin L, Duan J, Bian X, Yu S . Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1):61. PMC: 7285581. DOI: 10.1186/s13058-020-01296-5. View

Finn R . Targeting Src in breast cancer. Ann Oncol. 2008; 19(8):1379-1386. DOI: 10.1093/annonc/mdn291. View

Ahluwalia M, de Groot J, Liu W, Gladson C . Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett. 2010; 298(2):139-49. PMC: 3212431. DOI: 10.1016/j.canlet.2010.08.014. View

Greish K, Sawa T, Fang J, Akaike T, Maeda H . SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J Control Release. 2004; 97(2):219-30. DOI: 10.1016/j.jconrel.2004.03.027. View

Leveque D, Becker G, Bilger K, Natarajan-Ame S . Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clin Pharmacokinet. 2020; 59(7):849-856. DOI: 10.1007/s40262-020-00872-4. View

Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong T . Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007; 67(5):2226-38. DOI: 10.1158/0008-5472.CAN-06-3633. View

10.

Yeatman T . A renaissance for SRC. Nat Rev Cancer. 2004; 4(6):470-80. DOI: 10.1038/nrc1366. View

11.

Wang D, Jiang Z, Ben-David Y, Woodgett J, Zacksenhaus E . Molecular stratification within triple-negative breast cancer subtypes. Sci Rep. 2019; 9(1):19107. PMC: 6911070. DOI: 10.1038/s41598-019-55710-w. View

12.

Pichot C, Hartig S, Xia L, Arvanitis C, Monisvais D, Lee F . Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer. 2009; 101(1):38-47. PMC: 2713704. DOI: 10.1038/sj.bjc.6605101. View

13.

He C, Hu Y, Yin L, Tang C, Yin C . Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010; 31(13):3657-66. DOI: 10.1016/j.biomaterials.2010.01.065. View

14.

Yao Y, Chu Y, Xu B, Hu Q, Song Q . Risk factors for distant metastasis of patients with primary triple-negative breast cancer. Biosci Rep. 2019; 39(6). PMC: 6549086. DOI: 10.1042/BSR20190288. View

15.

Fan P, McDaniel R, Kim H, Clagett D, Haddad B, Jordan V . Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. Eur J Cancer. 2012; 48(18):3488-98. PMC: 3518839. DOI: 10.1016/j.ejca.2012.04.020. View

16.

Duckett D, Cameron M . Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol. 2010; 6(10):1175-93. PMC: 2940961. DOI: 10.1517/17425255.2010.506873. View

17.

Perou C . Molecular stratification of triple-negative breast cancers. Oncologist. 2010; 15 Suppl 5:39-48. DOI: 10.1634/theoncologist.2010-S5-39. View

18.

Finn R, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss L . Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011; 17(21):6905-13. DOI: 10.1158/1078-0432.CCR-11-0288. View

19.

Maeda H . SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev. 2001; 46(1-3):169-85. DOI: 10.1016/s0169-409x(00)00134-4. View

20.

Greish K, Jasim A, Parayath N, Abdelghany S, Alkhateeb A, Taurin S . Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme. J Drug Target. 2017; 26(8):692-708. DOI: 10.1080/1061186X.2017.1419357. View